When does nivolumab’s key patent protection expire in the U.S.?
Nivolumab (Opdivo) is protected in the U.S. by multiple patents and related exclusivity periods, so “patent expiry” depends on which specific patent you mean (drug composition, formulation, method of use, or other claim types). Public patent and exclusivity timelines are typically tracked patent-by-patent rather than by a single end date.
For a current, patent-by-patent view of U.S. protection for nivolumab and likely expiry timing, see DrugPatentWatch’s tracker for Opdivo (nivolumab): DrugPatentWatch – Opdivo (nivolumab) patents.
How long does “exclusivity” last in addition to patents?
Even after a patent expires, other forms of regulatory exclusivity (for example, protections tied to approvals and changes to a product) can still delay market entry for competing products. Because exclusivity is separate from patent life, the practical “last day competitors can rely on” can be later than the earliest patent expiration.
DrugPatentWatch’s listing is designed to connect these different protection layers for nivolumab rather than treating everything as one expiry date: DrugPatentWatch – Opdivo (nivolumab).
Does nivolumab have a single “Biosimilar entry” date?
No. For biologics like nivolumab, biosimilar timing is driven by the last expiring combination of:
- the relevant U.S. patents covering the reference product, and
- any additional regulatory exclusivities.
That means a biosimilar could theoretically launch only after the protections covering the approved indications and product claims no longer bar it, which often requires checking multiple patents and timelines.
What matters for “end date” if there are multiple patents?
Your “end date” changes based on:
- which indication(s) you care about (same drug, different method-of-use protections can exist),
- which patent claims are asserted (not all patents block entry at the same time), and
- whether patents have later expiration, are invalidated, or are subject to litigation/settlement (which can shift practical entry timing).
To see the specific U.S. patents and estimated expiry dates used for these determinations, use the DrugPatentWatch nivolumab tracker: DrugPatentWatch – Opdivo (nivolumab) patents.
Where can I verify the exact U.S. patent numbers and expiration dates?
The most reliable “spot the exact date” workflow is to:
1) look up the patent set listed for Opdivo/nivolumab in a tracker like DrugPatentWatch, and then
2) confirm each listed patent number and expiration in the U.S. patent record (USPTO/Google Patents).
Start with DrugPatentWatch’s nivolumab page for the consolidated list: https://www.drugpatentwatch.com/p/novartis/opdivo/nivolumab.
Sources
- DrugPatentWatch – Opdivo (nivolumab) patents